Browse our 650+ Publications​

Latest Publications

A phase 2, randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma

Holstein S, et al.
Blood
April 2025
Authors and Affiliates
Sarah A. Holstein,1 Shebli Atrash,2 Hira Mian,3 Meletios A. Dimopoulos,4 Fredrik Schjesvold,5 Rakesh Popat,6 Nishi Shah,7 Moshe E. Gatt,8 Christian B. Gocke,9 Laurent Frenzel,10 Cyrille Touzeau,11 Meral Beksac,12 Salomon Manier,13 Hila Magen,14 Patrick Travis,15 Omar Nadeem,16 Kaveri Suryanarayan,17 Cheryl Li,17 Shuli Li, 17 Allison Nelson,17 Dasha Cherepanov,17 Xavier Parot,17 and Dan T. Vogl18 Affiliations: 1. University of Nebraska Medical Center, Omaha, NE, USA 2. Levine Cancer Institute, Charlotte, NC, USA 3. McMaster University, Hamilton, Canada 4. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Department of Medicine, Korea University, Seoul, South Korea Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece 5. Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway 6. University College London Hospital, London, UK 7. Montefiore Medical Center, New York, NY, USA 8. Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel 9. Johns Hopkins University, Baltimore, MD, USA 10. Necker Hospital, Paris, France 11. Centre Hospitalier Universitaire de Nantes, Nantes, France 12. Istinye University Ankara Liv Hospital, Ankara, Turkey 13. Lille University Hospital, Lille, France 14. Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel 15. Highlands Oncology Group, Springdale, AR, USA 16. Dana-Farber Cancer Institute, Boston, MA, USA 17. Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA 18. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy

Bal S, et al.
Blood Cancer Journal
April 2025
Authors and Affiliates
Susan Bal 1,2,8, Tylan Magnusson1,8, Gayathri Ravi1,2, Smith Giri1,2, Kelly Godby1,2, Binod Dhakal 3, Natalie S. Callander 4,Rebecca W. Silbermann5, Bhagirathbhai Dholaria 6, Vishnu B. Reddy7 and Luciano J. Costa 1,2 1Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. 2 O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, AL, USA. 3 Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 4 Division of Hematology, Department of Medicine, Medical Oncology and Palliative Care, Wisconsin Institutes for Medical Research, Madison, WI, USA. 5 Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 6 Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. 7 Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. 8 These authors contributed equally: Susan Bal, Tylan Magnusson.

Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential

Gregory W, et al.
Clinical Cancer Research
April 2025
Authors and Affiliates
Walter M. Gregory1, Thomas J. Prior2, J. Blake Bartlett3, Pieter Sonneveld4, Meletios A. Dimopoulos5, Philippe Moreau6, Saad Usmani7, and Thierry Facon8 1Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom. 2Janssen Research & Development, Spring House, Pennsylvania. 3Janssen Research & Development, LLC, Raritan, New Jersey. 4Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 5Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece. 6Hematology Department, University Hospital Hˆotel- Dieu, Nantes, France. 7Memorial Sloan Kettering Cancer Center, New York, New York. 8University of Lille, CHU Lille, Lille, France.

Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP

Nijland M, et al.
Blood Advances
April 2025
Authors and Affiliates
Marcel Nijland 1, Djamila E Issa 2, Johanna A A Bult 1, Dries Deeren 3, Gerjo A Velders 4, Marten R Nijziel 5, Yorick Sandberg 6, Vibeke Kj Vergote 7, Margriet Oosterveld 8, Rob Fijnheer 9, Rolf Brouwer 10, Rinske Boersma 11, Kalung Wu 12, Laurens Nieuwenhuizen 13, Joost Sp Vermaat 14, Roel J W van Kampen 15, Wim E Terpstra 16, Sylvia Snauwaert 17, Marjolein Wm van der Poel 18, Eva de Jongh 19, Marc Durian 20, Leonie Strobbe 21, Aart Beeker 22, Alain Pa Gadisseur 23, Roos Van Rijn 24, Otto J Visser 25, Jeanette Doorduijn 26, Tjeerd J F Snijders 27, Matthijs H Silbermann 28, Daphne de Jong 29, Martine E D Chamuleau 30, Rogier Mous 31, Mathilde Jalving 1, Heleen Visser-Wisselaar 32, Sonja Jansen van den Bergh 32, Gerben Jc Zwezerijnen 33, Edwin Bremer 1, Mirian Brink 34, Arjan Diepstra 1, Dana A Chitu 35, Harry R Koene 36, Josée M Zijlstra 37 1University Medical Center Groningen, Groningen, Netherlands. 2Jeroen Bosch hospital, Den Bosch, Netherlands. 3AZ Delta, Roeselare, Belgium. 4Hospital Gelderse Vallei, Ede, Netherlands. 5Catharina Cancer Institute, Eindhoven, Netherlands. 6Maasstad Hospital, Rotterdam, Netherlands. 7UZLeuven, Leuven, Belgium. 8Canisius-Wilhelmina Hospital, Nijmegen, Netherlands. 9Meander Medical Centre, Amersfoort, Netherlands. 10Reinier de Graaf Hospital, Delft, Netherlands. 11Amphia Hospital, Breda, Netherlands. 12ZNA Stuivenberg, Antwerp, Belgium. 13Maxima Medical Center, Veldhoven, Netherlands. 14Leiden University Medical Center, Leiden, Netherlands. 15Zuyerland Medical Center, Sittard-Geleen, Netherlands. 16Olvg, Amsterdam, Netherlands. 17AZ Sint-Jan Hospital Bruges, Bruges, Belgium. 18Maastricht University Medical Center, Maastricht, Netherlands. 19Albert Schweitzer Hospital, Dordrecht, Netherlands. 20ETZ Tilburg, Tilburg, Netherlands. 21Gelre ziekenhuizen, Zutphen, Netherlands. 22Spaarne Gasthuis, Hoofddorp, Netherlands. 23Antwerp University Hospital, Edegem, Belgium. 24Leeuwarden, Netherlands. 25Isala Clinic, Zwolle, Netherlands. 26Erasmus MC, Cancer Institute, Rotterdam, Netherlands. 27Medical Spectrum Twente (MST), Enschede, Netherlands. 28Tergooi Hospital, Hilversum, Netherlands. 29Netherlands Cancer Institute, Amsterdam, Netherlands. 30Amsterdam UMC, Vrije Universtiteit, Cancer Center Amsterdam, Amsterdam, Netherlands. 31University Medical Center Utrecht, Utrecht, Netherlands. 32Erasmus MC Cancer Institute, Rotterdam, Netherlands. 33Amsterdam UMC, location VUMC, Cancer Center Amsterdam, Amsterdam, Netherlands. 34Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands. 35Erasmus MC Rotterdam, The Netherlands, Rotterdam, Netherlands. 36St. Antonius Ziekenhuis, Nieuwegein, Netherlands. 37Amsterdam UMC, Amsterdam, Netherlands.

Daratumumab for newly diagnosed multiple myeloma: pooled analysis of patients aged >/65 years from GRIFFIN and PERSEUS

Rodriguez-Otero P, et al.
Clinical Lymphoma Myeloma & Leukemia
April 2025
Authors and Affiliates
Paula Rodriguez-Otero,a Peter M. Voorhees,b Mario Boccadoro,c Jacob Laubach,d Hermann Einsele,e Douglas W. Sborov,f Meletios A. Dimopoulos,g Annemiek Broijl,h Roberto Mina,i Andrew Spencer,j Fredrik Schjesvold,k Rebecca Silbermann,l Francesca Gay,i Luciano J. Costa,m Aurore Perrot,n Yanfang Liu,o Jianping Wang,p Anna Sitthi-Amorn,p Robin Carson,p Annelore Cortoos,q Saad Z. Usmani,r Paul G. Richardson,d Philippe Moreau,s Pieter Sonneveld,h and Jonathan L. Kaufmant aDepartment of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra, Spain; bLevine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, United States; cMyeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; dDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States; eUniversity Hospital Würzburg, Department of Internal Medicine II, Würzburg, Germany; fHuntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States; gNational and Kapodistrian University of Athens, Athens, Greece; hDepartment of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands; iDivision of Hematology 1, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, and Department 3 of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; jMalignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia; kOslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, and KG Jebsen Center for B-cell Malignancies, University of Oslo, Oslo, Norway; lKnight Cancer Institute, Oregon Health & Science University, Portland, OR, United States; mUniversity of Alabama at Birmingham, Birmingham, AL, United States; nCHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France; oJohnson & Johnson, Beijing, China; pJohnson & Johnson, Spring House, PA, United States; qJohnson & Johnson, Horsham, PA, United States; rMemorial Sloan Kettering Cancer Center, New York, NY, United States; sHematology Department, University Hospital Hôtel-Dieu, Nantes, France; tWinship Cancer Institute, Emory University, Atlanta, GA, United States.

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

Mateos M, et al.
Lancet Oncology
April 2025
Authors and Affiliates
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Mai Ngo, Eva G Katz, Maria Krevvata, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Meletios A Dimopoulos University Hospital of Salamanca/IBSAL/Cancer Research Center–IBMCC (USAL-CSIC), Salamanca, Spain (M-V Mateos PhD); Cancer Center Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain (Prof J San-Miguel MD); IRCCS Azienda Ospedaliero– Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy (Prof M Cavo MD); Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan (K Suzuki MD); University of Chicago Medical Center, Chicago, IL, USA (Prof A Jakubowiak MD); Department of Hematology, Oncology and Stem Cell Transplantation, Nuremberg General Hospital, Paracelsus Medical School, Nuremberg, Germany (Prof S Knop MD); Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium (Prof C Doyen MD); Champalimaud Centre for the Unknown, Lisbon, Portugal (P Lucio MD); Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary (Z Nagy MD); University Hospital and Masaryk University Brno, Brno, Czech Republic (L Pour MD); Department of Hematology and Cancer Prevention in Chorzów, Faculty of Health Sciences in Bytom, Medical University of Silesia in Katowice, Katowice, Poland (S Grosicki MD); Clinica de Tratamento E, Cuiaba, Brazil (A Crepaldi MD); Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria, Terni, Italy (Prof A M Liberati MD); Andrew Love Cancer Centre, University Hospital Geelong, Geelong, VIC, Australia (P Campbell MD); Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (Prof S-S Yoon MD); Medinvest- Institute of Hematology, Tbilisi, Georgia (G Iosava MD); Matsuyama Red Cross Hospital, Matsuyama, Japan (T Fujisaki MD); Leicester Royal Infirmary – Haematology, Leicester, UK (M Garg MD); Janssen Research & Development, LLC, Titusville, NJ, USA (M Ngo PhD); Janssen Research & Development, LLC, Raritan, NJ, USA (E G Katz PhD; K Bolyard MS, F Borgsten MD); Janssen Research & Development, LLC, Spring House, PA, USA (M Krevvata PhD, R Carson MD); Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece (Prof M A Dimopoulos MD)

Project EVOLVE: An international analysis of post-immunotherapy lineage switch, an emergent form of relapse in leukemia

Silbert S, et al.
Blood
April 2025
Authors and Affiliates
Sara Silbert (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Alexander Rankin (Nationwide Children's Hospital, United States) Chloe Hoang (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Alexandra Semchenkova (Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Russian Federation) Regina Myers (Children's Hospital of Philadelphia, United States) Elena Zerkalenkova (Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Russian Federation) Hao-Wei Wang (National Institutes of Health, United States) Alexandra Kovach (Children's Hospital Los Angeles, United States) Constance Yuan (NCI/NIH, United States) Dana Delgado Colon (NCI/NIH, United States) Loic Vasseur (Hôpital Saint Louis, France) Alex Bataller (The University of Texas MD Anderson Cancer Center, United States) Samuel John (Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, United States) Kaylyn Utley Lyons (Children's Hospital Colorado, University of Colorado School of Medicine, Denver CO, United States) Barbara Friedes (Children's Hospital of Philadelphia, United States) Anna Alonso-Saladrigues (Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu. Barcelona. Spain; Institut de Recerca Sant Joan de Déu, Barcelona, Spain; Medicine and Surgery School. University of Barcelona. Barcelona, Spain., Spain) Hisham Abdel-Azim (Loma Linda University school of Medicine, Cancer Center, Children Hospital and Medical Center, United States) Estelle Balducci (Hôpital Necker-Enfants Malades, APHP, France) Ahmed Aljudi (Children's Healthcare of Atlanta, United States) Marie Balsat (Hôpital Lyon sud, Pierre-Bénite, France) D. Biery (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Aghiad Chamdin (Children's hospital of Michigan/Central Michigan University, United States) Bill Chang (OHSU, United States) Raymund Cuevo (Inova Schar Cancer Institute, United States) Barbara De Moerloose (Ghent University Hospital, Belgium) David Dickens (Stead Family Children's Hospital University of Iowa, United States) Ulrich Duffner (Pediatric Bone Marrow Transplantation & Cellular Therapy, Corewell Health Helen DeVos Children's Hospital, 100 Michigan Street NE Grand Rapids, MI 49503, United States) Nicolas Duployez (CHU Lille, France) Firas El Chaer (Division of Hematology and Oncology, Department of Medicine, The University of Virginia, United States) Michelle Elliott (Mayo Clinic, United States) Gabriele Escherich (University hospital Hamburg Eppendorf, Germany) Sneha Fernandes (Great Ormond Street Hospital for Children, London, United Kingdom) Mandi Fitzjohn (Children's Hospital Colorado, University of Colorado School of Medicine, Denver CO, United States) Zhubin Gahvari (University of Wisconsin School of Medicine and Public Health, United States) Stephan Grupp (Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Perelman School ofMedicine, University of Pennsylvania, Philadelphia, PA, USA, United States) Rui Rochelle He (Department of Pathology, Inova Fairfax Medical Campus. Inova Health System, Falls Church, VA 22042, United States) Cynthia Harrison (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Christopher Hergott (Brigham and Women's Hospital, United States) Emily Hsieh (Children's Hospital Los Angeles, United States) Annette Kim (University of Michigan, United States) Dennis Kuo (University of California San Diego, United States) Daniel Larson (Mayo Clinic, United States) Benjamin Lee (UC Irvine Health, United States) Thibaut Leguay (Hopital du Haut-Lévèque, France) R. Lindsley (Dana-Farber Cancer Institute, United States) Abhishek Mangaonkar (Mayo Clinic, United States) Kerstin Mezger (Clinic of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, Germany) Holly Pacenta (Cook Children's Medical Center, United States) Jing Pan (Beijing GoBroad Hospital, China) Marlie Provost (HCA HealthONE - Rocky Mountain Hospital for Children, United States) Latika Puri (Loma Linda University Children' Hospitalpital, United States) Sunil Raikar (Emory University, United States) Armando Martinez (National Institutes of Health, United States) Isabella Bristol (National Institutes of Health, United States) Kyle Murphy (National Institutes of Health, United States) Lauren Reiman (Children's Hospital Los Angeles, United States) Michele Redell (Texas Children's Hospital, Baylor College of Medicine, United States) Kelly Reed (University of Virginia School of Nursing, United States) Gabrielle Roth Guepin (Chu nancy, France) Jeremy Rubinstein (Cincinnati Children's Hospital Medical Center, United States) Süreyya Savaşan (Children's Hospital of Michigan, United States) Kristian Schafernak (Phoenix Children's Hospital, United States) Alexandra McLean Stevens (Texas Children's Hospital Downloaded from http://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2024026655/2367646/blood.2024026655.pdf by guest on 11 April 2025 Baylor College of Medicine, United States) Aimee Talleur (St. Jude Children's Research Hospital, United States) Naomi Torres Carapia (Children's Hospital Los Angeles, United States) Jacques Vargaftig (Institut Curie, France) Anant Vatsayan (Children's National Hospital, United States) Matthias Wölfl (University Hospital Wurzburg, Germany) Liping Zhao (State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China) Susana Rives (Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu Barcelona, Spain) Vanessa Fabrizio (University of Colorado Anschutz Medical Campus, United States) Koji Sasaki (The University of Texas MD Anderson Cancer Center, United States) Ibrahim Aldoss (City of Hope National Medical Center, United States) Nicolas Boissel (Hopital Saint-Louis, AP-HP, France) Susan Rheingold (The Children's Hospital of Philadelphia, United States) Kara Davis (Stanford University, United States) Sara Ghorashian (University College London Great Ormond Street Institute of Child Health, United Kingdom) Elad Jacoby (Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, Israel) Alexander Popov (National Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation) Adam Lamble (Seattle Children's Hospital, United States) Nirali Shah (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States)

Optimal MRD-based endpoint to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Giri S, et al.
Blood
April 2025
Authors and Affiliates
Smith Giri MD, MS1, Binod Dhakal MD2, Natalie S Callander MD3, Eva Medvedova MD4, Kelly Godby MD1, Bhagirathbhai R. Dholaria MD5, Susan Bal MD1, Gayathri Ravi MD1, Saurabh Chhabra MD MS1, Rebecca W Silbermann MD2, Luciano Costa MD PhD1. 1Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 2 Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 3Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI 4Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 5Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma

Lopedote P, et al.
British Journal of Haematology
April 2025
Authors and Affiliates
Paolo Lopedote1 Geoffrey Shouse1 Sandrine Puverel1 Alexandra Muir1 Carly Roleder1 Peter Sportelli2 Hari Miskin2 Lu Chen1 Tycel J. Phillips1 Alexey V. Danilov1 1City of Hope National Medical Center, Duarte, California, USA 2TG Therapeutics Inc., Morrisville, North Carolina, USA

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma

Shah N, et al.
Journal of Clinical Oncology
March 2025
Authors and Affiliates
Nirav N. Shah, MD, MS1 ; Alfredo S. Colina, BA2 ; Bryon D. Johnson, PhD1; Aniko Szabo, PhD3; Fateeha Furqan, MD1; Tyce Kearl, MD, PhD1 ; Dina Schneider, PhD4 ; Marlenny Vargas-Cortes, BS5 ; Jessica L. Schmeling, BS5 ; Michael B. Dwinell, PhD2; Katie Palen, BS1; Walter Longo, MD1; Peiman Hematti, MD1 ; Anthony E. Zamora, PhD2 ; Parameswaran Hari, MD, MS1 ; Daniel Bucklan, MD6; Ashley Cunningham, MD7; Mehdi Hamadani, MD1 ; and Timothy S. Fenske, MD1 1BMT & Cellular Therapy Program, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 2Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI 3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 4Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD 5Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 6Department of Radiology, Medical College of Wisconsin, Milwaukee,WI 7Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
Previous Next